The company

AAVantgarde Bio, a clinical stage Milan-based international biotechnology start-up that has developed proprietary Adeno-Associated Viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy, and supported by Sofinnova Partners.